Arvelle Therapeutics is based in Basel, Switzerland. It has raised $223M in total funding.
Arvelle Therapeutics funding overview
Arvelle Therapeutics is based in Basel, Switzerland. Arvelle Therapeutics has raised $223M in total disclosed funding. That places its disclosed total in the $100M–$250M range. The round record for Arvelle Therapeutics runs through 2023; nothing later has been disclosed. Investors on record include Life Sciences Partners, HIG BioHealth Partners, NovaQuest Capital Management. 3 distinct backers are named across the disclosed rounds.
Arvelle Therapeutics at a glance
Total raised
$223M
Latest round date
June 2023
Headquarters
Basel, Switzerland
Notable investors
Life Sciences Partners, HIG BioHealth Partners, NovaQuest Capital Management
Frequently asked about Arvelle Therapeutics funding
How much has Arvelle Therapeutics raised?
Arvelle Therapeutics has raised $223M in total disclosed funding across the rounds on record.
Who has invested in Arvelle Therapeutics?
Life Sciences Partners, HIG BioHealth Partners, NovaQuest Capital Management are named among the investors backing Arvelle Therapeutics.
What was the latest Arvelle Therapeutics funding round?
No round stage has been disclosed for Arvelle Therapeutics.
Where is Arvelle Therapeutics based?
Arvelle Therapeutics is based in Basel, Switzerland.
When did Arvelle Therapeutics last raise?
The last disclosed Arvelle Therapeutics round closed in June 2023.
Arvelle Therapeutics totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in Basel below to benchmark round size and investor mix.
